| ChiCGB vs BEAM in High-risk or R/R Lymphomas (NCT05466318) | Sichuan University | 2022-07-01 |
| SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies (NCT05398614) | Hebei Senlang Biotechnology Inc., Ltd. | 2022-05-01 |
| Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL (NCT05557903) | Lanzhou Institute of Biological Products Co., Ltd | 2021-12-20 |
| Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma (NCT04928105) | Hebei Senlang Biotechnology Inc., Ltd. | 2021-01-27 |
| CAR-37 T Cells in Hematologic Malignancies (NCT04136275) | Marcela V. Maus, M.D.,Ph.D. | 2020-06-19 |
| Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma (NCT04233697) | Columbia University | 2020-02-01 |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas (NCT04104776) | Novartis Pharmaceuticals | 2019-09-18 |
| Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma (NCT03921879) | Oncotartis, Inc. | 2019-07-29 |
| ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy (NCT04121507) | GWT-TUD GmbH | 2019-06-24 |
| IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (NCT03902184) | Innate Pharma | 2019-05-22 |
| Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma (NCT03703375) | Celgene | 2018-11-06 |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma (NCT03161223) | University of Virginia | 2018-05-30 |
| Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response (NCT03154710) | Weprom | 2017-07-12 |
| Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas (NCT02158975) | University of Michigan Rogel Cancer Center | 2014-09-01 |
| A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NCT01421667) | Seagen Inc. | 2011-08-01 |
| A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms (NCT01309789) | Seagen Inc. | 2011-02-01 |
| Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma (NCT00418535) | Samsung Medical Center | 2006-04-01 |
| UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas (NCT00082017) | National Cancer Institute (NCI) | 2004-04-05 |
| Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas (NCT00069238) | National Cancer Institute (NCI) | 2003-09-19 |
| PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) (NCT00043368) | Pfizer | 2002-09-01 |
| Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies (NCT00038883) | M.D. Anderson Cancer Center | 2001-04-09 |
| Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies (NCT00038376) | M.D. Anderson Cancer Center | 1990-05-08 |